does retatrutide help with addiction Why Is Gaining Attention in Peptide Weight Loss Therapy GLP-1 medications get at the

doi:10.1056/NEJMoa1105816 Greenway FL

Understanding how they actually work can help set realistic expectations

Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

It also describes recent changes to the administrations plans for temporary coverage of GLP-1s in Medicare, including an indefinite delay in implementation of the BALANCE Model in Part D and an extension of a separate short-term program, called the Medicare GLP-1 Bridge, which was originally scheduled to run from July-December 2026 but will now run through the end of 2027

What about ANY of the cardiometabolic data for the 104 week extension arm, especially the 4mg max tolerated dose and the placebo arm MTD

Restraints & Challenges: A shortage of numerous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has occurred, owing to a large increase in demand